乐天医疗与OEP集团合作拓展亚洲市场，推广用于复发性头颈癌的光免疫疗法-动脉网

Rakuten Medical Partners with OEP Group to Expand in Asia, Promoting Photoimmunotherapy for Recurrent Head and Neck Cancer

GeneOnline 等信源发布 2025-06-26 17:11



可切换为仅中文







by Oscar Wu

作者：奥斯卡·吴

Share To

分享到

On June 25, 2025, Rakuten Medical announced a partnership with Cyntec, a subsidiary of OEP Group, to drive the development and commercialization of photoimmunotherapy using the Alluminox™ platform in Taiwan, Singapore, Malaysia, and the Philippines. The agreement includes upfront payments and milestone-based royalties, aiming to integrate cancer treatment expertise from the U.S., Japan, and Taiwan..

2025年6月25日，乐天医疗宣布与OEP集团旗下的子公司Cyntec达成合作，推动使用Alluminox™平台在台湾、新加坡、马来西亚和菲律宾进行光免疫疗法的开发和商业化。该协议包括预付款和基于里程碑的特许权使用费，目标是整合来自美国、日本和台湾的癌症治疗专业知识。

Head and neck cancer has long had a high incidence rate in Asia—particularly in Taiwan, where approximately 9,000 new cases are diagnosed annually among men, with nearly 40% already in stage IV at diagnosis. While traditional treatments like surgery, radiation, and chemotherapy remain standard, their invasiveness and side effects often hinder long-term adherence..

头颈癌在亚洲的发病率一直很高，尤其是在台湾，每年男性大约有9000例新诊断病例，其中近40%在诊断时已处于第四期。虽然手术、放疗和化疗等传统治疗方法仍是标准方案，但其侵入性和副作用常常影响患者的长期依从性。

Rakuten Medical President

乐天医疗总裁

Minami Maeda

南真由子

stated, “The Alluminox™ platform delivers a form of photoimmunotherapy that combines precision targeting with low invasiveness, giving patients a chance to extend their lives while maintaining quality of life.”

声明说：“Alluminox™ 平台提供了一种光免疫疗法形式，它结合了精准靶向和低侵入性，让患者在延长生命的同时保持生活质量。”

Photoimmunotherapy Unveiled: The Cancer Cell “Detonator”

光免疫疗法揭秘：癌细胞“引爆器”

Photoimmunotherapy works by combining a targeted antibody with a photosensitive dye to create a selective compound, activated by near-infrared light. The technology uses the IR700 dye from the Alluminox™ platform, which can kill cancer cells precisely without causing thermal damage. After injection, the compound selectively binds to tumor cells and awaits light activation for up to 24 hours.

光免疫疗法通过将靶向抗体与光敏染料结合，形成一种选择性化合物，并由近红外光激活。该技术使用来自Alluminox™平台的IR700染料，能够精准杀死癌细胞而不引起热损伤。注射后，该化合物选择性地结合到肿瘤细胞上，并在长达24小时内等待光激活。

Upon exposure to specific red light wavelengths, the dye rapidly disrupts the cell membrane, triggering “immediate explosive cell death.”.

当暴露于特定红光波长时，这种染料会迅速破坏细胞膜，触发“立即的爆炸性细胞死亡”。

This destruction not only controls the local tumor but may also activate a systemic immune response. The ruptured cancer cells release antigens, which are captured by antigen-presenting cells (APCs), leading to T-cell activation and broader tumor eradication. Dr.

这种破坏不仅控制了局部肿瘤，还可能激活全身的免疫反应。破裂的癌细胞释放抗原，这些抗原被抗原呈递细胞（APCs）捕获，导致T细胞活化和更广泛的肿瘤清除。

Kuan-Chou Lin

林冠州

, former president of the

，前总统

Taiwan Association of Oral and Maxillofacial Surgeons

台湾口腔颌面外科协会

, emphasized that this therapy could treat surgically inaccessible tumors and may even suppress distant metastases—achieving both local and systemic effects.

，强调这种疗法可以治疗手术无法触及的肿瘤，甚至可能抑制远处转移——实现局部和系统的影响。

High Mortality from Head and Neck Cancer in Taiwanese Men: Complexity and Recurrence Pose Challenges

台湾男性头颈癌死亡率高：复杂性和复发性带来挑战

“Early symptoms are subtle, and diagnosis often comes too late,” said Dr.

“早期症状很隐匿，往往诊断出来时已经太晚了，”博士说。

Yi-Shing Leu

吕义兴

, President of the Taiwan Head and Neck Oncology Society. In Taiwan, oral cancer makes up about 50% of head and neck cancers, with oropharyngeal cancer comprising another 20–30%. The rise in HPV infections has further increased incidence. Risky habits—such as smoking, drinking, and betel nut chewing—are prevalent among men, while low screening rates in certain occupational groups mean that nearly 40% are diagnosed at a late stage, missing the opportunity for early cure..

台湾头颈肿瘤学会理事长。在台湾，口腔癌占头颈癌约50%，口咽癌则占20-30%。随着HPV感染增加，口咽癌发生率也持续上升。男性因吸烟、饮酒、嚼槟榔等危险习惯，加上部分职业族群筛检率较低，导致近40%患者确诊时已属晚期，错失早期治愈机会。

Advanced cases require long, complex treatments with poor prognosis. Even after initial therapy, up to 40% face recurrence or metastasis. Traditional approaches like surgery, radiation, and chemotherapy are limited in repeat use and patient tolerance. Recurrence treatment is often a major hurdle.

晚期病例需要长期、复杂的治疗，且预后较差。即使经过初始治疗，仍有高达40%的患者面临复发或转移。手术、放疗和化疗等传统方法在重复使用和患者耐受性方面存在局限性。复发治疗往往是主要障碍。

Dr. Lu likened treatment planning to “military strategy,” where physicians must anticipate and prepare for each stage. Introducing innovative therapies like photoimmunotherapy could increase treatment flexibility and options, offering more hope for patients and a new direction for clinical care.

吕博士将治疗计划比作“军事战略”，医生必须预测并为每个阶段做好准备。引入光免疫疗法等创新疗法可以提高治疗的灵活性和选择，为患者提供更多的希望，并为临床护理提供新的方向。

Japan’s Nearly 1,000 Patient Real-World Evidence Serves as a Reference for Asia

日本近1000名患者的真实世界证据可作为亚洲的参考

Since gaining market approval in Japan in 2020, Alluminox™-based photoimmunotherapy has been used in about 180 medical institutions, with nearly 1,000 patients treated. Real-world data shows a disease control rate (DCR) exceeding 95% and an objective response rate (ORR) over 60% with primarily localized side effects like redness and pain.

自2020年在日本获得市场批准以来，基于Alluminox™的光免疫疗法已在约180家医疗机构使用，治疗了近1000名患者。真实世界数据显示，疾病控制率（DCR）超过95%，客观缓解率（ORR）超过60%，主要副作用为局部发红和疼痛等。

It has demonstrated good tolerance and minimal systemic toxicity, indicating high feasibility and potential for repeat use..

它表现出良好的耐受性和极小的系统毒性，表明其具有高可行性和重复使用的潜力。

Dr. Lin added that up to 50% of Taiwanese head and neck cancer patients who chew betel nut face higher risks of recurrence or secondary tumors. These patients often cannot tolerate a second round of traditional treatments, making photoimmunotherapy—being

林博士补充说，高达50%的台湾头颈癌患者嚼槟榔，他们面临更高的复发或二次肿瘤风险。这些患者通常无法耐受第二轮传统治疗，使得光免疫疗法变得尤为重要。

repeatable

可重复的

，

minimally invasive

微创的

, and

，以及

non-disruptive to organ structures

对器官结构无破坏性

—an attractive alternative, especially for hard-to-reach areas like deep head and neck regions, skull base, or larynx. However, he also noted that it is less suitable for distant metastases or tumors hidden behind bone structures.

——一个极具吸引力的替代方案，特别是对于难以触及的区域，如深部头颈部、颅底或喉部。然而，他也指出，对于远处转移或隐藏在骨结构后的肿瘤，它不太适用。

Rakuten Eyes Indication Expansion, OEP Group Targets Funding and Insurance Coverage

乐天眼科扩张，OEP集团目标融资与保险覆盖

With Taiwan’s mature clinical infrastructure and ample patient base, it is expected to be one of the main recruitment sites, with an estimated 400 patients, subject to adjustments. This partnership between Rakuten Medical and OEP Group extends beyond medicine, incorporating commercial strategies and policy advocacy..

凭借台湾成熟的临床基础设施和充足的患者基础，预计将成为主要招募地点之一，估计约有400名患者，具体人数可能会有所调整。乐天医疗与OEP集团的合作不仅限于医药领域，还涵盖了商业策略和政策倡导。

OEP Group CEO Calvin Tsai said they aim to secure inclusion of photoimmunotherapy in Taiwan’s cancer drug fund and national health insurance to reduce financial burdens. They also plan to collaborate with major medical centers to establish standardized treatment protocols and education systems to accelerate clinical adoption..

OEP集团首席执行官蔡明杰表示，他们的目标是确保将光免疫疗法纳入台湾的癌症药物基金和全民健康保险，以减轻患者的经济负担。他们还计划与主要的医疗中心合作，建立标准化的治疗方案和教育系统，以加速临床应用。

President Maeda emphasized that the Alluminox™ platform is not just a single product but a scalable technology applicable to various solid tumors. This Asian expansion marks the beginning of broader applications in skin, bladder, and even esophageal cancers, paving the way for next-generation immunotherapy..

前田总裁强调，Alluminox™平台不仅仅是一个单一的产品，而是一种可扩展的技术，适用于各种实体肿瘤。此次亚洲市场的拓展标志着该技术在皮肤癌、膀胱癌甚至食道癌中的广泛应用的开始，为下一代免疫疗法铺平了道路。

Singapore Becomes Latest Asian Country to Sign Merck Deal for Oral COVID-19 Pill

新加坡成为最新一个与默克公司签署口服新冠药物协议的亚洲国家

Defeating Head and Neck Cancer, From Combination Therapy to Photoimmunotherapy

从联合疗法到光免疫疗法，战胜头颈癌

Singapore and Japan Collaborate on Groundbreaking Robotic Telesurgery Trial

新加坡与日本合作开展突破性的机器人远程手术试验

AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore

阿斯利康在新加坡投资15亿美元的ADC制造工厂

[email protected]

电子邮件地址

Author